Glycopyrrolate NDC 79739-7097

NDC codes

FDA NDC Directory

Product NDC (as listed)79739-7097Labeler and product segments. Claims need a package NDC.

Product NDC at billing width79739-7097Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
79739-7097-1	79739709701	100 TABLET in 1 BOTTLE, PLASTIC (79739-7097-1)Marketed from Mar 12, 2012

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Glycopyrrolate
Generic name (nonproprietary): glycopyrrolate
Active ingredients: Glycopyrrolate — 1.5 mg/1
Dosage form: Tablet
Route: Oral
Labeler: LGM PHARMA SOLUTIONS, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 091522
Marketing start: Mar 12, 2012
Listing expires: Dec 31, 2026
Other FDA classes: Cholinergic Antagonists (Mechanism)
Identifiers: Product ID 79739-7097_9004cf80-5ded-482e-89ca-841fcd89f778SPL ID 9004cf80-5ded-482e-89ca-841fcd89f778SPL set ID 392a969d-1e14-4ad8-835c-a47be4983067RxCUI 1247658UNII V92SO9WP2IUPC 0379739709714
Pharmacologic class: Anticholinergic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N479739709701 followed by a unit qualifier and the quantity

Package 79739-7097-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 27, 2023.

Indications (excerpt from the label)

INDICATIONS AND USAGE For use as adjunctive therapy in the treatment of peptic ulcer.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 091522

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 091522
Product	Strength	Form · route	Labeler	Product NDC
Glycopyrrolate	Glycopyrrolate 1.5 mg/1	TabletOral	FH2 Pharma LLC	72887-160
Glycateglycopyrrolate	Glycopyrrolate 1.5 mg/1	TabletOral	Intra-Sana Laboratories	80056-160